Answers are grounded in this paper and cite their sources.
Human sodium-glucose cotransporter 2 (hSGLT2) is a membrane-embedded renal transporter and an established therapeutic target for type 2 diabetes. Hyperoside, myricetin, cyanidin-3-O-glucoside and isoliquiritigenin were investigated as a chemically diverse panel of natural scaffolds using a multi-scale computational workflow combining redocking-validated molecular docking, reconstruction of an unresolved transporter segment, molecular dynamics (MD) in an explicit POPC bilayer, molecular mechanics/Poisson–Boltzmann surface area (MM/PBSA) calculations, principal component and free-energy landscape analyses and density functional theory (DFT). The membrane simulations preserved the global hSGLT2 fold while revealing distinct ligand-dependent binding behaviours. Myricetin and cyanidin-3-O-glucoside exhibited limited positional deviations; hyperoside achieved persistent accommodation following an initial adjustment, whereas isoliquiritigenin underwent a marked late rearrangement. Ensemble-based energetic analysis prioritized cyanidin-3-O-glucoside, while hyperoside and myricetin formed an energetically comparable intermediate group and isoliquiritigenin displayed the least favourable profile. Electronic-structure analysis further characterized cyanidin-3-O-glucoside as the most responsive ligand within the DFT subset. Collectively, these findings indicate that glycone-assisted polar anchoring, aromatic complementarity and restricted conformational flexibility promote persistent hSGLT2 recognition. Direct hSGLT2 inhibition and hSGLT1 counter-screening assays remain necessary to establish potency and selectivity.
No takes yet. Share an insight, caveat, or question.
Khibech et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: